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Abstract
Background: Efficient targeted gene transfer and cell type specific transgene expression are important for the safe and
effective expression of transgenes in vivo. Enveloped viral vectors allow insertion of exogenous membrane proteins into
their envelopes, which could potentially aid in the targeted transduction of specific cell types. Our goal was to specifically
target cells that express the T cell tropic HIV-1 envelope protein (Env) using the highly specific interaction of Env with
its cellular receptor (CD4) inserted into the envelope of an HIV-1-based viral vector.
Results: To generate HIV-1-based vectors carrying the CD4 molecule in their envelope, the CD4 ectodomain was fused
to diverse membrane anchors and inserted together with the HIV-1 coreceptor CXCR4 into the envelopes of HIV-1
vector particles. Independent of the type of CD4 anchor, all chimeric CD4 proteins inserted into HIV-1 vector envelopes
and the resultant HIV(CD4/CXCR4) particles were able to selectively confer neomycin resistance to cells expressing the
fusogenic T cell tropic HIV-1 Env protein. Unexpectedly, in the absence of Env on the target cells, all vector particles
carrying the CD4 ectodomain anchored in their envelope adhered to various cell types without infecting these cells. This
cell adhesion was very avid. It was independent of the presence of Env on the target cell, the type of CD4 anchor or the
presence of CXCR4 on the particle. In mixed cell populations with defined ratios of Env+/Env- cells, the targeted
transduction of Env+ cells by HIV(CD4/CXCR4) particles was diminished in proportion to the number of Env- cells.
Conclusion:  Vector diversion caused by a strong, non-selective cell binding of CD4+-vector particles effectively
prevents the targeted transduction of HIV-1 Env expressing cells in mixed cell populations. This Env-independent cell
adhesion severely limits the effective use of targeted HIV(CD4/CXCR4) vectors designed to interfere with HIV-1
replication in vivo. Importantly, the existence of this newly described and remarkably strong CD4-dependent cell adhesion
suggests that the multiple viral efforts to reduce CD4 cell surface expression may, in part, be to prevent cell adhesion to
non-target cells and thereby to increase the infectivity of viral progeny. Preventing CD4 down-modulation by HIV-1 might
be an effective component of a multi-faceted antiviral strategy.
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Background
The interaction of the human immunodeficiency virus
type 1 (HIV-1) envelope protein (Env) with its cellular
receptor CD4 [1] was recognized early as an opportunity
to selectively inhibit HIV-1 infection by competition with
soluble CD4 or by targeting HIV-1 infected cells with cyto-
cidal molecular conjugates of CD4 such as CD4-Pseu-
domonas exotoxin [2,3]. CD4 is a transmembrane protein
and can be inserted into viral envelopes [4,5]. We postu-
lated that defective, CD4 encoding HIV-1 vectors could be
designed to target HIV-1 infected cells and to interfere
with HIV-1 replication. In a role reversal, such HIV(CD4)
particles would target HIV-1 Env+ cells with Env providing
membrane fusion activity. Defective HIV-1 genomes that
interfere with HIV-1 replication by expression of a chi-
meric CD4 protein and/or a multitarget-ribozyme were
previously designed in our lab [6,7]. Several replication
competent enveloped viral vectors that are able to target
HIV-1 infected cells were developed from vesicular stoma-
titis virus (VSV) [8] and rabies virus [9]. Targeted retroviral
vectors have previously been used including avian leuco-
sis virus (ALV) [4], Moloney murine leukemia virus [10],
HIV-1 and simian immunodeficiency virus type 1 [11].
Chimeric CD4 proteins Figure 1
Chimeric CD4 proteins. (A) Membrane anchors. The CD4 ectodomain of CD4 (1) was linked to five heterologous mem-
brane anchors: the glycosylphosphatidyl inositol region of the DAF protein (2), the transmembrane and cytoplasmic domains of 
either HIV-1 Env (5) or the VSV G (6), or the entire gp41 region of HIV-1 Env with (3) or without (4) the proteolytic cleavage 
site. (B) Western blot analysis of CD4 and the chimeric CD4 proteins. The six proteins were expressed from the CMV pro-
moter in pCR3 after transfection of Hek293 cells and analyzed by Western blot using anti-CD4 antibodies. (C) Intracellular and 
cell surface expression. Intracellular expression of chimeric CD4 proteins after DNA transfection in HeLa cells was evaluated 
using immunofluorescent staining of fixed cells after cell permeabilization and compared to cell surface expression of CD4 
without cell permeabilization.Retrovirology 2005, 2:80 http://www.retrovirology.com/content/2/1/80
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Most of these particles carry, in addition to CD4, one of
the coreceptors CXCR4 or CCR5 in their envelopes.
Altering viral envelopes to target select cell types remains
a challenge and mechanisms for the sorting and insertion
of membrane proteins into viral envelopes are not fully
understood [12]. Some enveloped viruses like rabies virus
appear more restrictive with respect to the origin of the
cytoplasmic domain for insertion of CD4 and CXCR4 [9]
as compared to VSV [13], a related rhabdovirus. HIV-1
appears less restrictive with respect to insertion of foreign
membrane proteins [13-18]. Extensive studies identified
many cellular membrane proteins, which are inserted into
the envelopes of budding viruses (for review see [19]).
Insertion of cellular ICAM-1, for example, can promote
HIV-1 infection of specific cell types such as CD4+ T-lym-
phocytes and memory CD4+ T cells [20-22] and will prob-
ably influence viral propagation in vivo.
In this communication, we focus on the functional activi-
ties of several chimeric CD4 proteins after their insertion
into HIV-1 envelopes. During wild-type HIV-1 infection,
insertion of CD4 into HIV-1 envelopes is efficiently
blocked by mechanisms that involve the viral Vpu, Nef
and Env proteins [23,24]. As a result, CD4 down-modula-
tion increases Env expression at the cell membrane for
better insertion into viral envelopes and thereby increases
virus release and infectivity [25-32] while preventing
superinfection of the HIV-1 infected cells.
An inverse relationship between the amount of surface
CD4 expression and the infectivity and release of viral
progeny has been described [33]. Previous studies on the
effect of CD4 on HIV-1 infectivity and particle release
were carried out when some of the viral mechanisms for
CD4 down-modulation were still active. The present study
describes the insertion of diverse chimeric CD4 proteins
into HIV-1 vector envelopes in the absence CD4 down-
modulation. This communication focuses on the conse-
quences of inserting CD4 into HIV-1 vector envelopes.
The study reports a novel, highly effective CD4-dependent
cell binding activity, which does not reduce the specificity
of targeting cells expressing T cell tropic HIV-1 Env protein
but greatly reduces its efficacy in heterogeneous cell pop-
ulations. These findings may provide a new rationale for
the virally mediated down-modulation of CD4, which
could have important implications for HIV-1 infectivity in
vivo.
Results
Structure and expression of chimeric CD4 proteins
For the targeting of cells that express HIV-1 Env, several
chimeric CD4 proteins were assembled by PCR DNA
fusion (Figure 1A). Each protein contained 397 amino
acids of the CD4 ectodomain including the signal peptide.
To compare the potential roles of the CD4 membrane
anchor and cytoplasmic domains during vector assembly,
the CD4 ectodomain was fused to a glycosylphosphati-
dylinositol (gpi) anchor [34], or it was fused to the trans-
membrane and cytoplasmic tail regions of either VSV G
protein or the HIV-1 Env protein. Two additional CD4
constructs contained the CD4 ectodomain fused to the
entire gp41 region of HIV-1 Env. The amino end of the
gp41 region was extended into the gp120 region of Env,
20 amino acids beyond the proteolytic cleavage site at the
gp120/gp41 junction. The Ile-Glu cleavage site itself was
either left unchanged (CD4/gp41+) or it was deleted
(CD4/gp41-).
Native CD4 and the five chimeric CD4 proteins were
expressed after DNA transfection of Hek293 cells. The
proteins migrated according to their predicted molecular
weight (Figure 1B). Only CD4/gp41+ is shown in Figure
1B, the migrations of both CD4/gp41 proteins were simi-
lar and gave rise to the same major and a minor protein
species. We found no evidence for proteolytic cleavage.
The expression levels differed between the individual chi-
meric CD4 proteins. The two larger chimera containing
the cytoplasmic portions of HIV-1 Env appeared to be
expressed at slightly lower levels. A similar difference was
observed by immunofluorescence of transfected cells (Fig-
ure 1C). Gentle permeabilization of the fixed cells
allowed a comparison of intracellular and cell surface
expression of the chimeric CD4 proteins. Each protein
was transported to the plasma membrane and was availa-
ble for potential incorporation into vector envelopes.
Insertion of the chimeric CD4 DNAs into the pCR3 plas-
mid allowed expression from either the CMV or T7 RNA
polymerase promoter. After DNA transfection, the func-
tionality of the CD4 proteins was initially evaluated in
HeLa cells by a syncytia-forming assay. Infection of trans-
fected HeLa cells with a vaccinia virus recombinant encod-
ing T7 RNA polymerase allowed higher expression levels
of the chimeric CD4 proteins in an increased number of
cells. Co-infection of the cells with a vaccinia virus recom-
binant encoding the HIV-1 Env provided the cell fusion
function. Syncytia formation was detected with all except
the two CD4/gp41 chimeric proteins, however, as shown
below, all CD4 chimera including the CD4/gp41 proteins
were functional Env receptors after insertion into defec-
tive HIV-1 particles. Syncytia formation through CD4-Env
interactions most likely requires a high density of CD4
expression at the cell surface and/or a conformational
change, presumably neither of which were provided by
the CD4/gp41 proteins.
Defective HIV-1 packaging construct
A replication-incompetent HIV-1 packaging construct,
HDPack1, was generated by deleting part of the HIV-1Retrovirology 2005, 2:80 http://www.retrovirology.com/content/2/1/80
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Generation of HIV(CD4) particles Figure 2
Generation of HIV(CD4) particles. (A) HDPack1. Three deletions were made in pNL4-3 DNA, an infectious clone of HIV-
1 [62], and the SV40 polyadenylation site was added to create the defective HIV-1 helper virus construct, HDPack1. HIV-1-
Neo is a defective HIV-1 DNA construct derived from HIV-1 HXB2 DNA with part of env replaced by the SV40 promoter and 
neomycinr gene [63]. (B) and (C) Sucrose gradient fractionation of HIV(CD4) particles. HIV particles without CD4 or carrying 
either CD4 or CD4/gpi were isolated after transfection of HeLa, HeLaT4 and HeLaS2 cells with pHDPack1 DNA. The particles 
were concentrated by centrifugation onto a 65 % sucrose cushion followed by separation through a 15–60 % sucrose gradient. 
A portion of the particles isolated from HeLa cells was pretreated with Triton X-100 prior to centrifugation to solubilize the 
viral membrane. The p24 (B) and CD4 (C) concentrations of each gradient fraction were determined by ELISA. HIV(w/o CD4) 
particles (● ), Triton X-100 treated HIV(w/o CD4) particles (X), HIV(CD4) () and HIV(CD4/gpi+) particles (). (D) Immuno-
precipitation of HIV(CD4) particles with anti-CXCR4 antibody. Pseudotype virions were isolated after co-transfections of 
HDPack1 and pCR3-CD4 DNA in either NIH 3T3 () and COS-7 (● ) cells or human embryonic kidney 293 () and HeLa 
(X) cells. The amounts of immunoprecipitated p24 antigen were determined by ELISA and are shown as a percentage of the 
total amount of input p24 antigen.
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packaging signal, most of Env and the entire Nef region of
the infectious HIV-1 DNA clone pNL4-3 (Figure 2A). A
SV40 polyadenylation site replaced the remaining part of
the 3' LTR. Cotransfection of HDPack1 with HXN, a min-
imal vector construct that encodes a neomycin resistance
gene [35], into BOSC cells that constitutively express the
MMLV ecotropic Env protein [36], generated a MMLV
Env+ pseudotype lentiviral vector, which was able to con-
fer neomycin resistance by stable transduction of NIH3T3
cells (data not shown). This demonstrated that HDPack1
provided all necessary structural proteins for pseudotype
vector formation and for stable gene transfer.
Incorporation of CD4 into vector envelopes
Cotransfection of HDPack1 with CD4 or any of the five
chimeric CD4 DNAs into HeLa cells yielded approxi-
mately 15–25 ng p24/ml in the cell supernatant two days
after transfection. Approximately one half of the total syn-
thesized p24 antigen was released by the cells and could
be immunoprecipitated by anti-CD4 antibody. Single
DNA transfections of HDPack1 into HeLaT4 or HeLaS2
cells resulted in higher yields of CD4 carrying particles
(over 100 ng/ml). HelaT4 and HeLaS2 cells constitutively
express high levels of CD4 and CD4/gpi, respectively.
Sucrose gradient analysis of supernatants from HDPack1
transfected cells revealed a peak of p24 antigen, which
contained the vector particles (Figure 2B) harvested from
HeLa, HeLaT4 or HeLaS2 cells. Over 90% of the p24 in
cell supernatants were associated with either vector parti-
cles or microvesicles that are simultaneously released by
the cell and cannot be separated by this gradient [37]. Sol-
ubilization of the viral membrane by 0.4% Triton X-100
shifted the p24 antigen to the top of the gradient (Figure
2B). The CD4 peak coincides with the p24 antigen peak
(Figure 2C). 1 ng of p24 corresponds to 1–2 × 107 mature
and immature virus particles. If all CD4 molecules in the
cell supernatants were only associated with p24 contain-
ing vector particles and each contained 1000–2000 mole-
cules of p24, we estimate that a single particle would carry
approximately 30–130 CD4 or CD4/gpi molecules in
their envelope. This estimate must be reduced by an
unknown amount of CD4 or CD4/gpi molecules that
could be associated with microvesicles.
Insertion of CXCR4 into vector envelopes
During infection, HIV-1 uses CD4 as its primary receptor
and a member of the chemokine receptor family like
CXCR4 or CCR5 as a coreceptor [38,39]. It was uncertain
whether endogenous levels of CXCR4 in HeLa cell mem-
branes would be sufficient for incorporation. HIV-1 has
been shown to exclude the insertion of the coreceptors
CXCR4, CCR5 and CCR3 into its envelope [40]. Defective
HIV-1 particles were generated by transfecting pHDPack1
DNA into either the human HeLa and Hek293 or mouse
NIH3T3 and African green monkey COS-7 cell lines. Anti-
CXCR4-antibodies precipitated fifty percent of p24 anti-
gen of particles generated in the two human cell lines (Fig-
ure 2D), but not with particles generated in NIH3T3 or
COS-7 cells. In a separate experiment, CD4- HDPack1 par-
ticles isolated from HeLa cells could also be precipitated
with anti-CXCR4 antibodies as efficiently as CD4+ parti-
cles generated from HeLaT4 and HeLaS2 cells, suggesting
that both, CXCR4 and CD4 are independently inserted
into vector envelopes.
Targeting and stable transduction of Env expressing cells
Particles carrying the different chimeric CD4 proteins and
CXCR4 were isolated from cell supernatants after cotrans-
fections of Hek293 cells with chimeric CD4 and HIV-1-
Neo DNAs. Equal amounts of these HIV-1-Neo particles
(1 ng p24) were used to infect HIV-1 envelope protein
expressing TF228 (Env+) cells as well as their parental
BJAB (Env-) cells (Figure 3). The stable transduction of
Env+ cells demonstrated that the different chimeric CD4
proteins are functional receptors for Env and that the
Stable transduction of Env+ cells by HIV-1-Neo(CD4/ CXCR4) particles Figure 3
Stable transduction of Env+ cells by HIV-1-Neo(CD4/
CXCR4) particles. (A) Vector particles isolated from 
Hek293 cells after single transfections of HIV-1-Neo or after 
co-transfections of HIV-1-Neo with DNAs encoding either 
CD4 or the five individual chimeric CD4 proteins or VSV G 
protein. (B) Particles were harvested after single transfection 
of HIV-1-Neo into HeLaT4 or HeLaS2 cells stably expressing 
CD4 or CD4/gpi proteins, respectively. Equal amounts of 
particles (1 ng p24) were used to infect either 105 Env+ 
TF228 or Env- BJAB cells and neomycin-resistant cell colonies 
were selected.
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amount of endogenous CXCR4 expression in Hek293
cells is sufficient for functional incorporation into vector
envelopes.
Transduction by the CD4/gp41 chimeras also demon-
strates discordance between the ability of Env-CD4 inter-
actions to mediate viral entry and syncytia formation,
which was not observed with these two constructs. In
comparison, HIV(VSV G) vector particles, generated by
cotransfection of DNAs encoding the fusogenic VSV G
protein and HIV-1-Neo, transduced both Env+ and Env-
cells at similar high efficiencies of approximately 500 col-
onies/ng p24. This was about sevenfold more efficient
than the average of 67 colonies/ng p24 by the different
HIV-1-Neo(CD4) particles generated by DNA cotransfec-
tions. The differences in the expression levels of the vari-
ous chimeric CD4 proteins as shown in Figure 2 were not
reflected in the transduction efficiencies of the vectors.
In contrast, HIV-1-Neo(CD4) and HIV-1-Neo(CD4/gpi)
particles generated by single HIV-1-Neo DNA transfec-
tions of HeLaT4 or HeLaS2 cells, respectively, had approx-
imately three to fourfold higher transduction capabilities
as compared to vector particles that were generated by the
less efficient DNA cotransfections. This differs from
HIV(VSV G) pseudotypes that were also generated by
DNA cotransfections but have higher transduction effi-
ciencies because, unlike CD4+  particles, they are not
dependent on the fusogenic activity provided by HIV-1
Env+ expressing target cells.
Kinetics of HIV(CD4) particle adhesion to Env+ and Env- 
cells
Equal amounts of virus particles (ng p24) generated using
HDPack1 in HeLa cells were added to HeLa and CHO cells
that either transiently (HeLa cells infected with a vaccinia
virus recombinant expressing Env) or stably (CHO-WT)
express HIV-1 Env protein, respectively. Homologous
Env- cells (HeLa cells infected with vaccinia virus recom-
binant expressing T7 RNA polymerase or CHO-EE cells)
served as a control. Unexpectedly, CD4+  particles
adsorbed to Env+ and Env- HeLa as well as CHO cells (Fig-
ure 4A). Though Env expression on target cells was abso-
lutely required for transduction as shown in Figure 3,
particles carrying CD4 adhered to Env+ cells only about
1.5 times better than to Env- HeLa or CHO cells. Adhesion
to Env- cells was significantly reduced when the particles
did not carry CD4 in their envelope.
The kinetics of cell adhesion were similar for the five dif-
ferent HIV-1(CD4) particles. Positioning the CD4 ectodo-
main further outside the vector envelope, as in the CD4/
gp41 chimeras, did not significantly diminish binding
efficiency, suggesting that the observed cell adhesion is
independent of the type of CD4 membrane anchor. A
time course of vector binding at 4°C is shown in Figure
4B, which summarizes the contribution of the specific
CD4-Env dependent interaction to the overall cell adhe-
sion of the particles. In comparison, the particles adhered
less well when they did not carry CD4.
The binding of soluble CD4 to Env can be enhanced by
raising the temperature [41]. Particle adhesion was also
compared at room temperature and at 37°C, which
enhanced the binding activities proportionally. Signifi-
cant differences in the relative Env-dependent and Env-
independent cell adhesion by these particles were not
detected at the three temperatures. Unexpectedly, the rate
of Env-independent cell adhesion by CD4+particles
appears comparable to the rate of the CD4-Env binding.
Inhibition of cell adhesion by anti-CD4 antibodies and 
soluble CD4
The binding of CD4+ particles to Env+ cells was partially
inhibited by addition of polyclonal anti-CD4 antibody (1
mg/ml). CD4+particles were pre-incubated with polyclo-
nal anti-CD4 antibody before addition of Env+ or Env-
HeLa cells (Figure 4C, left panel). Higher antibody con-
centration did not further reduce cell adhesion below the
level observed for the binding of CD4+ particles to Env-
cells. The low level of background binding seen with Env-
cells was unaffected, demonstrating that Env-independent
cell adhesion was not blocked by polyclonal anti-CD4
antibody.
Preincubation of Env+ and Env- target cells with increasing
concentrations of soluble CD4 specifically inhibited the
binding of CD4+ particles (Figure 4C, right panel). Similar
concentrations of sCD4 (30 µg/ml) were needed to par-
tially reduce Env-dependent and Env-independent cell
adhesion. This suggests that the avidity of the Env-inde-
pendent binding of CD4+particles to Env- cells may be
similar to that of the Env-dependent CD4 binding.
Although cell adhesion by CD4+ particles (Figure 4C, left
panel) was only partially inhibited by anti-CD4 antibody,
transduction of Env+cells by HIV-1-Neo(CD4) and HIV-1-
Neo(CD4/gpi) particles was completely blocked by anti-
CD4 antibody as shown in Table 1. By comparison, HIV-
1-Neo(G) pseudotypes, which carry the VSV G protein,
were completely neutralized by anti-G antibody but not
by high amounts of anti-CD4 antibody. Env- cells were
only infected by HIV-1-Neo(G) and not by HIV-1-
Neo(CD4) particles. These results confirm the specificity
of the antibodies used and demonstrate that the Env-inde-
pendent cell adhesion by CD4+ particles does not result in
stable transduction. In contrast, the adhesion of particles
without CD4 to Env+ cells was low and unaffected by
either anti-CD4 antibody or sCD4.Retrovirology 2005, 2:80 http://www.retrovirology.com/content/2/1/80
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Cell adhesion by vector particles Figure 4
Cell adhesion by vector particles. Panel A: HIV particles without CD4, or carrying CD4 or one of the different chimeric 
CD4 proteins in their envelope, were generated by cotransfections with pHDPack1 in HeLa cells. Equal numbers (10 ng p24) 
of particles were adsorbed in suspension for 30 min at 4°C to 105 Env+ or Env- target cells (HeLa or CHO). The amount of 
adsorbed virus particles associated with the cell pellet was determined by p24 ELISA. Panel B: Time course of cell adhesion by 
HIV particles. Binding of HIV(CD4) particles to Env+ cells (), Env- cells (● ), or adhesion of HIV(w/o CD4) particles to Env+ 
cells (). Adsorption was normalized to the maximal amount of CD4+ particles adsorbed to HIV Env+ cells at 30 min (= 100). 
Contributions of the CD4-dependent, and the Env-dependent cell adhesion are indicated. Panel C: Inhibition of virus binding by 
either anti-CD4 antibody (left panel) or soluble CD4 (right panel). Equal p24 amounts of HIV(CD4) particles were adsorbed to 
either Env+ () or Env- () HeLa cells. The amounts of bound vectors were compared to the adsorption of HIV(w/o CD4) 
particles to Env+ cells (). Before cell adsorption, the vector particles were preincubated with increasing amounts of polyclonal 
antibody to CD4. Alternatively, with sCD4, the target cells were preincubated before addition of the vector particles.
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Vector generation in different host cells and targeting 
different cells
To confirm that this newly observed cell adhesion prop-
erty is unique to CD4 carrying vector particles, HIV(w/o
CD4), HIV(CD4) and HIV(CD4/gpi) particles were pro-
duced from three different cell lines: human HeLa, African
green monkey COS or mouse NIH3T3 cells. For cell adhe-
sion, the same amounts of particles were added to Env+
and Env- HeLa, COS, CHO or NIH3T3 target cells. Cell
adsorption of these particles is shown in Figure 5, which
was normalized to the adsorbed CD4+ vector of each vec-
tor/cell combination (= 100). Similar differences in cell
adhesion were observed with CD4+, CD4/gpi+ and parti-
cles without CD4 that were generated in the three cell
types when added to the four different Env- and Env+ tar-
get cell types. The cell adhesion by CD4+ and CD4/gpi+
particles from all cell types suggests that the presence of
the CD4 ectodomain plays an important role in Env-inde-
pendent cell adhesion by these particles.
Diminished targeting of Env+ cells in Env+/Env- cell mixtures
Expression of a chimeric CD4/Env protein from the HIV-
1 LTR has previously been shown to decrease HIV-1
spread in vitro, however, stable targeted transduction of
HIV-1 Env expressing cells by HIV(CD4) particles was not
detected by us previously [6,7]. A lack of CXCR4 insertion
can now be ruled out by the data presented above. We
hypothesized at the time that even at a low amount of
Env+ cells in the target cell population resulting from less
efficient transfections with Env-encoding DNA, the highly
specific cell targeting should remain effective unless access
to Env+ target cells was simply blocked physically by a
high cell density of Env- cells. The avid, Env-independent
cell adhesion by CD4+ particles described above, however,
could potentially provide an alternative explanation.
To determine the particle to cell ratio at which transduc-
tion is saturated, a constant amount of HIV-1-Neo(CD4/
CXCR4) particles (1 ng p24) was added to a cell suspen-
sion consisting of increasing amounts (104 to 105) of Env+
TF228 cells. The total volume of the suspension was main-
tained at 0.5 ml DMEM with 10% serum. Virus particles
were adsorbed for 40 min at 37°C. To prevent cell sedi-
mentation and to promote free access and random inter-
actions of the cells with the vector, the suspensions were
mixed every 10 min. Neomycin-resistant transformant
colonies were subsequently selected for two weeks in agar
and counted. Independent of the total number of Env+ tar-
get cells present, a constant number of approximately 300
neomycin-resistant colonies was selected. This indicated
that the amount of vector particles in the cell suspension
limited the total number of stable transformants within
the density range of Env+ target cells tested (Figure 6).
To evaluate the efficiency of Env+  cell targeting, Env+
(TF228) and Env- (BJAB) cells were mixed at defined
ratios. A constant amount of HIV-1-Neo(CD4/CXCR4)
particles was added to cell suspensions with increasing
ratios of Env- to Env+ cells. Each population contained 104
Env+ TF228 cells and increasing numbers (104 to 8 × 104)
of Env- BJAB cells, the parental cells of TF228. As shown in
Figure 6, addition of increasing numbers of Env- cells dra-
matically decreased the number of neomycin resistant col-
onies. At a 1:1 ratio of Env+:Env- cells and a total number
of 2 × 104 cells, the number of transformants was reduced
over fifty percent. While transduction of Env+ cells in this
mixed cell population remained selective, the efficiency of
cell targeting was severely diminished. The low cell den-
sity in this relatively large volume of medium, together
with the repeated mixing of the cell suspension make it
unlikely that Env- cells physically blocked access of the
vector to Env+ target cells.
These results suggest that the Env- cells effectively com-
peted with Env+ cells for the binding of HIV-1-Neo(CD4/
CXCR4) particles. If this competition was caused by CD4-
dependent adhesion to Env- cells as demonstrated in Fig-
ures 4 and 5, we would infer that its rate of cell binding
Table 1: Neutralization of vector infectivity by antibodies to CD4 and VSV Ga
Antibody: Nonec anti-CD4c anti-VSV Gc
Particleb Env+ Env- Env+ Env- Env+ Env-
H I V - 1 - N e o ( w / o  C D 4 ) 344034
HIV-1-Neo(CD4) 403 5 6 3 401 3
HIV-1-Neo(CD4/gpi) 363 2 7 3 391 4
HIV-1-Neo(G) 591 517 446 550 4 6
a105 Env+ TF228 or 105 Env- BJAB cells were infected and neomycin-resistant cell colonies were selected in soft agar and counted after two weeks. 
The average number of selected colonies is presented from at least two titrations.
b Vector particles were collected from human 293 cell supernatants after single DNA transfection with HIV-1-Neo or after cotransfection of HIV-
1-Neo DNAs with DNAs encoding either CD4, CD4/gpi or the glycoprotein G of vesicular stomatitis virus, respectively.
c1 ng p24 of each vector type was preincubated for 30 min with or without 2 mg/ml antibody directed either against the CD4 ectodomain or the 
vesicular stomatitis virus glycoprotein G prior to infections.Retrovirology 2005, 2:80 http://www.retrovirology.com/content/2/1/80
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would be similar to that of the specific binding of HIV-1-
Neo(CD4/CXCR4) particles to Env+ cells. Consequently,
stable transduction of Env+ cells may be severely dimin-
ished by this highly effective CD4-dependent adhesion to
Env- cells.
Discussion
Accomplishing functional insertion of CD4 and CXCR4
into HIV-1 vector envelopes is the initial step towards tar-
geting HIV-1 infected cells with the future long-term goal
to inhibit HIV-1 replication. The assembly and function-
ality of vector particles carrying different chimeric CD4
proteins in their envelopes revealed that protein insertion
into vector envelopes was readily achieved by either DNA
co-transfections or by using cells that constitutively
express CD4 or CD4/gpi. Significant differences in the tar-
geted transduction of Env+ cells were not detected after
replacing the transmembrane and cytoplasmic domains
of CD4 with corresponding regions of either the HIV-1
envelope protein, the VSV glycoprotein G or the gpi
anchor of the cellular DAF protein [42]. This indicates that
the origin of the CD4 anchor was not critical for receptor
function during infections, which is consistent with ear-
lier observations that Env binding needed for infection
maps near the amino terminus (amino acids 40–60) of
CD4 [43].
For targeted transduction of cells that constitutively
express the T cell tropic HIV-1 Env protein, vector inser-
tion of both, CD4 and the CXCR4 coreceptor is needed.
The level of endogenous CXCR4 expression in HeLa cells
was sufficient for functional insertion of the coreceptor
into vector particles and CXCR4 DNA co-transfection was
not required. We conclude that HIV-1 readily inserts
many viral and nonviral membrane proteins, and a large
number of cellular proteins have previously been identi-
fied in HIV-1 envelopes [11,14].
The transduction efficiencies of six different HIV(CD4)
pseudotypes generated by co-transfection of HIV-1-Neo
with a CD4 expression plasmid were very similar, giving
rise to approximately 70 neomycin-resistant colonies per
ng p24 (Figure 3). HIV-1-Neo DNA transfection of
HeLaT4 or S2 cells, which stably express CD4 and CD4/
gpi, respectively, produced higher titers of pseudotyped
particles yielding transduction efficiencies of approxi-
mately 280 colonies per ng p24. This compares favorably
with wild-type HIV-1, which, at 1–3 × 103 infectious units
per ng p24 [44], is only three to ten fold more infectious.
Thus exchanging the roles of viral and cellular membranes
during membrane fusion does not dramatically reduce
viral infectivity.
HIV-1-Neo(CD4/CXCR4) particles, independent of the
type of CD4 anchor, were able to target and selectively
infect cells expressing T cell tropic HIV-1 Env. In homoge-
nous Env+ cell populations, this transduction was effi-
cient. Unexpectedly, CD4+  particles also adhered very
efficiently to a variety of human and animal cell types that
do not express HIV-1 Env without leading to cell transduc-
tion. The competition between Env+ and Env- cells for
CD4+ particles in mixed cell populations (Figures 5 and
6), the time course of CD4+ particle binding to Env+ and
Env- cells (Figure 4B) and the inhibition of CD4+ particle
adhesion by anti-CD4 antibody and by sCD4 (Figure 4C)
all suggest that the specific Env-dependent and the Env-
independent cell binding by these particles may have sim-
ilar avidity. CD4-Env binding has a dissociation constant
(KD) of 5 nM, which is comparable to that of a good anti-
body-antigen binding complex [45]. Our studies focused
on the adhesion of entire virus particles to cells. Polyclo-
nal anti-CD4 antibodies, which blocked HIV-1-
Neo(CD4/CXCR4) or HIV-1-Neo(CD4/gpi/CXCR4)
transduction of Env+ cells (Table 1), did not completely
prevent Env-independent cell adhesion (Figure 4C, left
panel). This suggests either a CD4 domain that may be
involved in the Env-independent adhesion was not
blocked by the antibody, or alternatively, CD4 may have
recruited an additional membrane component into the
vector envelope, which causes the new cell adhesion by
the particles. In the latter case, the same or a similar mem-
brane component must be present on the various cell
types used in the studies.
The efficiency of this Env-independent cell adhesion by
CD4+ particles was unexpectedly high. At a ratio of 1 Env+
to 8 Env- cells, the transduction of Env+ cells was inhibited
by over ninety percent (Figure 6). HIV-1 is a cytolytic ret-
rovirus and the number of cells expressing HIV-1 Env in
vivo are few [46-48]. Although many silently infected cells
are present in lymph nodes, only a small fraction (1 in
300) generally expresses HIV-1 Env [49]. Since Env-inde-
pendent cell adhesion occurred with all CD4+ particles
and all cell types tested (Figure 4A and 5), we predict that
targeted HIV(CD4) particles will be unable to infect Env+
cells at high efficiency in vivo. This severely limits, if not
totally abolishes, the feasibility of such an antiviral
approach. Transduction of Env+  cells by HIV(CD4/
CXCR4) particles, similar to the particles used in the
present study, has previously been reported [11], however
the efficacy of cell targeting was not evaluated in mixed
cell populations. Without this challenge, the potential
limitations for cell targeting in vivo were not recognized.
Earlier assumptions that HIV(CD4/CXCR4) particles
could potentially target HIV-1 infected cells in patients
relied on the high specificity and presumed strength of the
CD4-Env interaction.
The first clinical trial using a HIV-1-based vector is cur-
rently in progress [50,51]. A vector was introduced at highRetrovirology 2005, 2:80 http://www.retrovirology.com/content/2/1/80
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Cell adhesion by CD4+ and CD4/gpi+ particles generated in different cell types Figure 5
Cell adhesion by CD4+ and CD4/gpi+ particles generated in different cell types. Vector particles without CD4 or 
with CD4+ or CD4/gpi+ were generated in three different producer cell lines by DNA co-transfections of HDPack1 with CD4 
or CD4/gpi encoding plasmids. Equal amounts of p24 vector particles (10 ng) were added to the same number of Env+ or Env- 
target cells (HeLa, COS-7, NIH 3T3 and CHO). Except for Env+ CHO-WT and Env- CHO-EE cells, the other Env+ target cells 
were generated by high multiplicity infections with a vaccinia virus recombinant expressing either HIV-1 Env (+) or with T7 
RNA polymerase (-) as a control. The amounts of adsorbed vector were normalized for each vector/target cell combination to 
the amount of HIV(CD4) vector adsorbed to Env+ target cells (= 100).
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efficiency into patients T4 lymphocytes ex vivo. The pur-
pose of this trial is to evaluate the safety of the HIV-1-
based vector and to render the cells resistant to endog-
enous HIV-1 strains, which previously did not respond to
antiviral drug cocktails. For gene therapy, effective trans-
gene expression in vivo generally requires, besides very
high in vivo grade vector titers, optimal access to the target
cell population. The ex vivo transduction of enriched
human T-lymphocytes by a HIV-1-based vector can be
expected to be much more efficient because this route of
transgene delivery avoids vector infusion into complex
cell populations or target tissues.
Vector distribution in vivo is likely to be affected by pro-
teins that are inserted into the vector envelope during viral
budding from the producer cell. The unexpected diversion
of targeted HIV(CD4/CXCR4) particles has important
general implications for the use of enveloped viral vectors
in vivo. It demonstrates that the vector producer cell can
greatly impact on the transduction efficiency of the vector
depending on the nature of the target cell within a com-
plex cellular environment in vivo. Insight from detailed
studies by several labs [19-22,52,53] can be expected to
help with the choice of vector producer cells for specific
cell targeting applications in the future.
Our study compared the cell adhesion and the infectivity
of vectors produced in the absence of Vpu, Nef and Env
expression, which allowed to focus on the immediate
effects of CD4 and CXCR4 insertion into vector enve-
lopes. During wild-type HIV-1 infection, CD4 and the
coreceptors CXCR4 and CCR5 are excluded from the HIV-
1 envelope through interactions with HIV-1 Nef protein
[40,54]. The insertion of endogenous CXCR4 from HeLa
and Hek293 cells was sufficient for the generation of
infectious HIV-1-Neo(CD4/CXCR4) particles. Without
Vpu, Env and Nef expression from both HDPack1 and
HIV-1-Neo, insertion of CD4 and CXCR4 appeared undis-
turbed and the resulting vector particles efficiently
infected homogeneous Env+ target cell populations. In
fact, their infectivity was surprisingly effective and not dra-
matically reduced as one might anticipate in comparison
to particles carrying the fusogenic VSV glycoprotein.
CD4 down-modulation benefits the release and the infec-
tivity of the released particles. Whether CD4-dependent
membrane adhesion already occurs intracellularly in the
absence of HIV Env is currently unknown. As shown here,
functional vector particles were efficiently released. Addi-
tional expression of Env interferes with CD4 cell surface
expression and vice versa. Particles containing both Env
and small amounts of CD4 could potentially be released
from the cell. Upon release, these particles may either
adhere directly to the cell from which they originated, or
they may bind to and be arrested by adjacent non-host
cells. In fact, a chimeric CD4 protein, which lacks the C-
terminus and is not down-modulated by proteolytic deg-
radation [55,56] may effectively inhibit HIV-1 replication
as previously suggested [7].
Vpu plays an important role in the down-modulation of
CD4. Vpu forms cationic-selective channels [57]. Amilo-
ride derivatives have been shown to be able to block Vpu
channel activity and to reduce HIV-like particle release
and viral replication in human macrophages [58,59].
From our studies presented here, we infer that the reduced
amount of particles released form T4 cells and macro-
phages in the absence of functional Vpu (or Nef) might
carry increased amounts of CD4 in their envelope and
thereby potentially decrease the HIV-1 infectivity through
cell adhesion to a majority of non-host cell types. More
detailed studies on the precise mechanism of the cell
adhesion and the resulting particle diversion are necessary
to better understand the potential involvement of CD4. If
Diversion of targeted HIV-1-Neo(CD4/CXCR4) particles Figure 6
Diversion of targeted HIV-1-Neo(CD4/CXCR4) par-
ticles. One ng of HIV-1-Neo(CD4/CXCR4) particles was 
adsorbed to homogenous populations of either Env+ TF228 
(•) or Env- BJAB cells (■ ), or to mixed cell populations con-
sisting of 104 Env+ cells plus increasing amounts 104-8 × 104 of 
Env- cells (❍ ). Stably transduced cells were selected in the 
presence of neomycin.
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confirmed, inhibiting Vpu and/or Nef activity may poten-
tially help augment the effectiveness of the current highly
active antiretroviral therapy.
Conclusion
Lentiviral vectors targeted to HIV-1 expressing cells could
potentially be part of an antiviral strategy. HIV-1-based
vectors, which carry CD4 in their envelope, do selectively
infect HIV-1 Env expressing cells, however, an unexpect-
edly avid and Env-independent cell adhesion by the same
CD4+ particles diminished the targeted transduction of
Env+ cells in mixed cell populations. Further studies on
the potential direct or indirect role of CD4 during this cell
adhesion are needed, which may provide an additional
rationale for the multiple efforts by HIV-1 to down-mod-
ulate CD4 expression prior to viral assembly. Without
CD4 down-modulation, insertion of CD4 into virus parti-
cle envelopes may reduce infectivity, thus viral mecha-
nisms to down-modulate CD4 could potentially become
antiviral targets. The apparent ease of inserting cellular
proteins from vector producer cells into HIV-1 envelopes
has important implications for transgene delivery by HIV-
1-based vectors as well as other enveloped viral vectors.
Depending on the target cell and its cellular environment
in vivo, the choice of vector producer cells could affect
infectivity and thereby vector efficacy during gene therapy.
Materials and methods
Cell types and cell culture
HeLa, HeLaT4 expressing CD4 protein [1], HeLaS2
expressing CD4/gpi protein (Ragheb JA: unpublished),
COS-7, Hek293 cells and NIH3T3 cells were grown in
Dulbecco's minimal essential medium (DMEM; GIBCO),
10% fetal bovine serum (FBS), 1% penicillin/streptomy-
cin. Chinese hamster ovary cells with (CHO-WT) or with-
out (CHO-EE) HIV-1 Env expression were grown in
GMEM-S media [60]. The human lymphoblastoid cell
line BJAB and its HIV-1 Env expressing progeny TF228
[61] were maintained in DMEM/16 % FBS/pen/strep sus-
pension cultures. Neomycin resistant colonies were
selected with 400 µg neomycin/ml in soft agar.
Chimeric CD4 proteins
(A) pCR3-CD4/gp41: CD4 and gp41 protein coding
regions derived from pHD1 [7] and pNL4-3 [62] were
fused by PCR [5] at pos. 1250 in CD4 and at pos. 7705 in
pNL4-3 using the fusion primer CCCCGGTGCAGCCAAT-
GATTGAACCATTAGGAGTAGC and the terminal primers
AAGCTTGGTTACCCAGGACC and GGAGTGTAT-
TAAGCTTGTG. The fusion product was ligated at HindIII
to gp41, pos. 8145 to 8887 of pNL4-3. A 1680 bp BstEII/
BssHII fragment of CD4/gp41 was transferred into pCD4/
G [5]. The complete CD4/gp41+ coding region (Xba1-
BssHII) was blunt-end ligated at EcoRV into pCR3 down-
stream of the CMV promoter. With CD4/gp41-, the prote-
olytic cleavage site Ile-Glu (ATT-GAA) was deleted in the
primers. (B) pCR3-CD4/G:CD4/G was excised from
pCD4/G using XhoI and BssHII. After filling in with Kle-
now fragment, blunt ended CD4/G was cloned into pCR3
at EcoRV. (C) pCR3-CD4/Env: A 1085 bp fragment
(BstEII-XhoI) was removed from pHD1 [7] and cloned
into BstEII-XhoI of pCR3-CD4/G. (D) pCR3-CD4: Part of
the CD4 coding region (603 BstXI-1737 BamHI) was
removed from pT4B [1] and cloned at BstX1 and BamH1
of pCD4/G. (E) pCR3-CD4/gpi was constructed by insert-
ing a EcoRI-HpaI fragment from the CD4/gpi [34] present
in LA4SN (Ragheb JA: unpublished) into EcoRI-EcoRV of
pCR3. Chimeric CD4 proteins were analyzed by Western
blot using monoclonal anti-human CD4 (Leu-3a) with
either [125I]-labeled S. aureus protein A or [125I]-labeled
sheep anti-mouse whole IgG antibody and visualized by
autoradiography. For immunofluorescent staining, cells
were fixed with 3% formaldehyde with and without per-
meabilization by 0.4% Triton X-100. Primary mouse
monoclonal antibody or polyclonal sheep anti-human
CD4 protein serum were used in combination with sec-
ondary donkey anti-mouse IgG or anti-sheep IgG, conju-
gated with fluorescent isothiocyanate (FITC).
Assembly of pHDPack1
For the generation of the HIV-1 packaging construct, several
deletions were introduced into pNL4-3 (1) DNA by PCR.
(A): a 654 bp fragment was amplified using primer (+)
GAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACT-
GGTGAGAGATGGGTGCGAGAGCGTCGG and primer (-)
GGCCCTGCATGCACTGGATG, deleting 39 bp (749–787),
and cleaved with BssHII and SphI. pNL4-3 was cleaved
with SphI (pos. 1404) and EcoRI (pos. 5743) resulting in a
4.3 kb fragment. Both fragments were ligated into BssHII
and EcoRI of pHD1 [7]. (B): PCR of pNL4-3 with the termi-
nal primers (+) CATAATAAGAATTCTGCAAC and (-)
CAAGTTAACAGCACTATTC and the fusion primers (+)
GGGATATTGATGTCTGTAGAATAGGAGCTTTGTTCCTT-
GGG and (-) CCCAAGGAACAAAGCTCCTATTCTACAGT-
CATCAATATCCC produced a 1457 bp fragment with a
1448 bp deletion in Env (pos. 6307–7755). It was cleaved
with EcoRI and HpaI. (C): A 240 bp fragment, containing
the poly(A) site of SV40, was amplified using (+)
TAGCCCGGGATAAGATACATTGATGAGT and (-) TAG-
GAATTCATCATAATCAGCCATACCAC and cleaved with
SmaI and EcoRI. The DNA from step (A) was cleaved with
EcoRI and the fragments from steps (B) and (C) were
inserted in a three-piece-ligation to generate pHDPack1.
The defective HIV-1-Neo construct has previously been
described [63]. Both, HDPack1 and HIV-1-Neo lack com-
plete Vpu, Nef and Env coding regions.
Generation of defective HIV-1 particles
HeLa, HeLaT4, HeLaS2, COS-7, 293 and NIH3T3 cells,
grown in 35 mm dishes were cotransfected with 2.5 µg ofRetrovirology 2005, 2:80 http://www.retrovirology.com/content/2/1/80
Page 13 of 15
(page number not for citation purposes)
pHDPack1 DNA and 2.5 µg of either CD4 or chimeric
CD4 DNA using calcium phosphate coprecipitation. 48
hrs after transfection, the medium was centrifuged and the
supernatant was filtered through 0.45 µm filter. The p24
concentration was determined and the virus was frozen at
-70°C. With CD4+ HeLaT4 and CD4/gpi+ HeLaS2 cells,
particles were generated after single transfections of either
HDPack1 or, when stable transductions were evaluated,
with HIV-1-Neo DNA. As a control for the functionality of
HDPack1 as a helper construct that provides all necessary
structural proteins, HXN(MMLV) pseudotypes were gen-
erated by cotransfection of HDPack1 and HXN DNAs [35]
into BOSC cells, which express ecotropic Moloney murine
leukemia virus Env protein [36]. With select particles,
vesicular stomatitis virus glycoprotein G (Indiana sero-
type) was inserted by co-transfection.
For separation on sucrose gradients, the particles were
concentrated by centrifugation onto a 65% sucrose pad at
150,000 × g for 60 min, resuspended in 0.5 ml of PBS and
separated on 4.5 ml continuous 15–60% sucrose gradi-
ents in PBS at 120,000 × g for 2 hours. P24 and CD4 of
each fraction were determined by ELISA. CD4+ particles
were precipitated with approximately 0.5 mg/ml of poly-
clonal antibody to human CD4 or rabbit anti-CXCR4
antibody (Millennium Biotechnology, CA). Antigen/anti-
body complexes were pelleted after binding to Protein-A-
Sepharose. The amounts of p24 antigen present in solubi-
lized virus particles were determined by ELISA. Polyclonal
rabbit anti-VSV G protein antibody was used to neutralize
HIV(G) pseudotype particles.
Enzyme-linked immunoadsorbent assay for p24 and CD4 
proteins
HIV-1 p24 protein was determined by p24 ELISA (Cellular
Products Inc.). CD4 was quantified by a modified ELISA
using 96 well Immulon-4 plate (Dynatech Laboratories,
Inc.) next to CD4 protein standards (Intracel Corpora-
tion) and 50 µl of anti-CD4 polyclonal antibodies (5 µg/
ml), followed by addition of 0.15 µg of alkaline phos-
phatase-conjugated anti-sheep IgG (Jackson ImmunoRe-
search Laboratories, Inc.) and nitrophenylphosphate as a
substrate. The reaction was stopped by 0.1 M EDTA and
quantified at 405 nm.
Viral cell adhesion assay
Target cells were grown to 85% confluence. HeLa, COS-7
and NIH3T3 cells were infected at a multiplicity of infec-
tion of 5 with a vaccinia virus expressing either HIV-1 Env
(vPE16) [64,65] or T7 polymerase (vTF7) [66]. Recom-
binant vaccinia virus infected cells as well as noninfected
stable CHO-WT Env+ cells and control CHO-EE cells were
incubated at 37°C for 24 hours. The cells were suspended
using a cell scraper and passed through a #16 needle. Cells
were washed with PBS and resuspended in DMEM/10%
FBS before virus adsorption. BJAB and TF228(Env+) sus-
pension cells were washed before adding virus.
Each cell adhesion reaction contained 105 cells and 10–20
ng p24/ml viral particles in a total volume of 0.5 ml. Each
reaction was incubated for 30 min at 4°C in 0.5 ml. After
adsorption, the cells were washed, pelleted in 10% FBS
medium and resuspended in 200 µl DMEM. P24 antigen
of solubilized particles was determined by ELISA.
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